Nektar Therapeutics NKTR Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Nektar Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The official record: Nektar Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nektar Therapeutics's total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nektar Therapeutics's total current liabilities?
- Nektar Therapeutics (NKTR) reported total current liabilities of $57.71M in Q1 2026.
- How has Nektar Therapeutics's total current liabilities changed year-over-year?
- Nektar Therapeutics's total current liabilities decreased by 18.6% year-over-year, from $70.93M to $57.71M.
- What is the long-term trend for Nektar Therapeutics's total current liabilities?
- Over 5 years (2020 to 2025), Nektar Therapeutics's total current liabilities has grown at a -14.3% compound annual growth rate (CAGR), from $115.78M to $53.54M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.